Statistiques de base
| CIK | 1807983 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Medicenna Therapeutics Corp
SEC Filings (Chronological Order)
Cette page fournit une liste complète et chronologique des documents déposés auprès de la SEC, à l'exclusion des documents relatifs à la participation que nous fournissons ailleurs.
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39458 MEDICENNA THERAPEUTICS CORP. (Exact name of registrant as specifie |
|
| May 13, 2024 |
EXHIBIT 99.1 Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting ASCO has informed the Company that the previously accepted MDNA11 oral abstract has been withdrawn due to alleged violation of their prior publication policy based solely on their review of the abstract presented at AACR 2024. Medicenna disagrees with ASCO’s decision as the AACR 2024 abstract was limited to |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of pr |
|
| May 10, 2024 |
As filed with the Securities and Exchange Commission on May 10, 2024 As filed with the Securities and Exchange Commission on May 10, 2024 Registration No. |
|
| May 10, 2024 |
MDNAF / Medicenna Therapeutics Corp. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Medicenna Therapeutics Corp. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 58490H107 (CUSIP Number) April 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| April 30, 2024 |
Exhibit 99.1 Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 30, 2024 – Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA) (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant’s name into English) 2 Bloor St. W. 7th Floor Toronto, Ontario M4W 3E2 Canada (Address of pr |
|
| April 30, 2024 |
PRE-FUNDED COMMON SHARE PURCHASE WARRANT Medicenna Therapeutics Corp. Exhibit 99.3 PRE-FUNDED COMMON SHARE PURCHASE WARRANT Medicenna Therapeutics Corp. Warrant Certificate No.: 2024-PFW-01 Number of Common Shares Purchasable: 5,141,388 Date: April 30, 2024 THIS PRE-FUNDED COMMON SHARE PURCHASE WARRANT CERTIFICATE (the “Pre-Funded Warrant”) certifies that, for value received, RA Capital Healthcare Fund, L.P. (the “Holder”) is entitled, upon the terms and subject to |
|
| April 30, 2024 |
FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.2 FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company Medicenna Therapeutics Corp. (the “Company”) 2 Bloor Street West, 7th Floor Toronto, Ontario M4W 3E2 2. Date of Material Changes April 26, 2024 3. News Releases A news release with respect to the material change referred to in this report was issued by the Company through the services of Globe Newswire on April 26, 20 |
|
| April 26, 2024 |
Exhibit 99.1 Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 26, 2024 – Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA)(MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineere |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant’s name into English) 2 Bloor St. W. 7th Floor Toronto, Ontario M4W 3E2 Canada (Address of pr |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| April 25, 2024 |
EXHIBIT 99.1 Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting Oral presentation of MDNA11’s Phase 1/2 ABILITY-1 Study will feature new and updated clinical data Updated bizaxofusp survival results from the Phase 2b recurrent glioblastoma trial versus propensity matched external control arm will also be presented as a poster TOR |
|
| April 22, 2024 |
April 22, 2024 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 United States of America Re: Medicenna Therapeutics Inc. Application for Withdrawal Post-Effective Amendment No. 1 to Form F-3 (File No. 333-269868) Filed April 16, 2024 under EDGAR code F-3/A Ladies and Gentlemen: In accordance with Rule 477(a) under the Securities Act of 1933, as amended, a |
|
| April 16, 2024 |
As filed with the Securities and Exchange Commission on April 16, 2024 As filed with the Securities and Exchange Commission on April 16, 2024 Registration No. |
|
| April 16, 2024 |
As filed with the Securities and Exchange Commission on April 16, 2024 As filed with the Securities and Exchange Commission on April 16, 2024 Registration No. |
|
| April 16, 2024 |
As filed with the Securities and Exchange Commission on April 16, 2024 As filed with the Securities and Exchange Commission on April 16, 2024 Registration No. |
|
| April 10, 2024 |
EXHIBIT 99.1 Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) 100% reduction of target lesions in one melanoma and one pancreatic cancer patient observed among 4 Partial Responses (PR) to date which include 2 |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| April 9, 2024 |
EXHIBIT 99.1 Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) MDNA113 is targeted to the tumor site where it is activated to simultaneously deliver two immunotherapies, an IL-2 superkine and anti-PD1 antibody, to the same cancer fighti |
|
| April 4, 2024 |
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference EXHIBIT 99.1 Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference TORONTO and HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will pre |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| March 6, 2024 |
EXHIBIT 99.1 Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting Pre-clinical data on Medicenna’s first-in-class Masked and Tumor Targeted Bifunctional Superkine, MDNA113, will also be presented at the Annual Meeting TORONTO and HOUSTON, March 06, 2024 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| February 21, 2024 |
MDNAF / Medicenna Therapeutics Corp. / Merchant Fahar - SC 13G/A Passive Investment SC 13G/A 1 tm246862d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Medicenna Therapeutics Corp. (Name of Issuer) Common Shares, No Par Value (Title of Class of Securities) 58490H107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 21, 2024 |
EX-99.1 2 tm246862d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common shares of Medicenna Therapeutics Corp. and further agree that this agreemen |
|
| February 14, 2024 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, David Hyman, Chief Financial Officer of Medicenna Therapeutics Corp. (“Medicenna”) certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Medicenna (the “issuer”) for the interim period ended December 31, 2023. 2. No misrepresentations: Based |
|
| February 14, 2024 |
Exhibit 99.1 Interim condensed consolidated financial statements of Medicenna Therapeutics Corp. (Expressed in Canadian Dollars) For the three and nine months ended December 31, 2023 Medicenna Therapeutics Corp. Interim Condensed Consolidated Statements of Financial Position (Expressed in thousands of Canadian Dollars, except for share and per share amounts) (Unaudited) December 31, March 31, 2023 |
|
| February 14, 2024 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Fahar Merchant, Chairman, President and Chief Executive Officer of Medicenna Therapeutics Corp. (“Medicenna”) certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Medicenna (the “issuer”) for the interim period ended December 31, 2023. 2. N |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address |
|
| February 14, 2024 |
Exhibit 99.2 Management’s Discussion and Analysis For the Three and Nine Months Ended December 31, 2023 DATE OF REPORT: February 14, 2024 MANAGEMENT’S DISCUSSION AND ANALYSIS The following management’s discussion and analysis (“MD&A”) has been prepared as at February 14, 2024 for the three and nine months ended December 31, 2023 and should be read in conjunction with the unaudited interim condense |
|
| February 14, 2024 |
EXHIBIT 99.1 Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose phase-2 eligible patients (N=13) that failed checkpoint inhibitor therapies, while maintaining an acceptable safety profile Tumor shrinkage was also o |
|
| February 13, 2024 |
EXHIBIT 99.1 Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors The ABILITY-1 Study is evaluating MDNA11, a highly selective long-acting IL-2 Superkine, in combination with KEYTRUDA® (pembrolizumab) for treatment of patients with advanced solid tumors MDNA11 continues to demonstrate encouraging s |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address |
|
| February 7, 2024 |
MDNA / Medicenna Therapeutics Corp / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 Medicenna Therapeutics Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 58490H107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 24, 2024 |
MEDICENNA THERAPEUTICS CORP. (the “Corporation”) NOTICE OF CHANGE OF AUDITOR Exhibit 99.1 MEDICENNA THERAPEUTICS CORP. (the “Corporation”) NOTICE OF CHANGE OF AUDITOR TO: Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission AND TO: MNP LLP (“MNP”) PricewaterhouseCoopers LLP (“PwC”) Pursuant to National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”), the Corporation hereby gives notice as follows: 1. On Dece |
|
| January 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant’s name into English) 2 Bloor St. W. 7th Floor Toronto, Ontario M4W 3E2 Canada (Address of |
|
| January 24, 2024 |
Exhibit 99.2 January 9, 2024 Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission Dear Sirs/Madames: Re: Medicenna Therapeutics Corp. (the “Company”) Pursuant to National Instrument 51-102 Continuous Disclosure Obligations, we have reviewed the information contained in the Notice of Change of Auditor of the Company dated January 9, 2024 (“the Notice”) |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address o |
|
| January 16, 2024 |
Medicenna Announces Appointment of New Auditor EXHIBIT 99.1 Medicenna Announces Appointment of New Auditor TORONTO and HOUSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced the appointment of MNP LLP (“MNP” or “Successor Auditor”) as auditor. The board of directors of the Comp |
|
| January 9, 2024 |
Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab EXHIBIT 99.1 Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab The ABILITY-1 Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with KEYTRUDA® (pembrolizumab) for treatment of patients with advanced solid tumors MDNA11 continues to demonstrate encouraging single-agent activity from the dose escalation portion of the ABI |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address o |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant’s name into English) 2 Bloor St. W. 7th Floor Toronto, Ontario M4W 3E2 Canada (Address of |
|
| January 5, 2024 |
Exhibit 99.2 December 20, 2023 To: Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission We have read the statements made by Medicenna Therapeutics Corp. in the attached copy of change of auditor notice dated December 20, 2023, which we understand will be filed pursuant to Section 4.11 of National Instrument 51-102. We agree with the statements in the c |
|
| January 5, 2024 |
MEDICENNA THERAPEUTICS CORP. (the “Corporation”) NOTICE OF CHANGE OF AUDITOR EX-99.1 2 tm242105d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 MEDICENNA THERAPEUTICS CORP. (the “Corporation”) NOTICE OF CHANGE OF AUDITOR TO: Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission AND TO: PricewaterhouseCoopers LLP (“PwC”) Pursuant to National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”), the Corporation hereby gives n |
|
| December 22, 2023 |
Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF EXHIBIT 99.1 Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF TORONTO and HOUSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that its shares will commence trading on the OTCQB Venture Market in the United State |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address |
|
| December 22, 2023 |
Medicenna Extends Period to Exercise Certain Warrants EXHIBIT 99.1 Medicenna Extends Period to Exercise Certain Warrants TORONTO and HOUSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical stage immunotherapy company focused on the development of Superkines, today announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant’s name into English) 2 Bloor St. W. 7th Floor Toronto, Ontario M4W 3E2 Canada (Address of |
|
| November 21, 2023 |
Exhibit 99.1 Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Gliobastoma at the 28th Annual Meeting of the Society for NeuroOncology Single treatment of bizaxofusp doubled mOS (14.5 months vs. 7.2 months) irrespective of IL4R expression (high or low) compared to patients treated in the external control arm Survival for bizaxofusp-treated patients incr |
|
| November 14, 2023 |
Interim condensed consolidated financial statements of Exhibit 99.1 Interim condensed consolidated financial statements of Medicenna Therapeutics Corp. (Expressed in Canadian Dollars) For the three and six months ended September 30, 2023 Medicenna Therapeutics Corp. Interim Condensed Consolidated Statements of Financial Position (Expressed in thousands of Canadian Dollars, except for share and per share amounts) (Unaudited) September 30, 2023 March 31 |
|
| November 14, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Fahar Merchant, Chairman, President and Chief Executive Officer of Medicenna Therapeutics Corp. (“Medicenna”) certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Medicenna (the “issuer”) for the interim period ended September 30, 2023. 2. |
|
| November 14, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Eamonn Peters, Vice President, Finance, acting as Chief Financial Officer of Medicenna Therapeutics Corp. (“Medicenna”) certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Medicenna (the “issuer”) for the interim period ended September 30, |
|
| November 14, 2023 |
EXHIBIT 99.5 Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights Cash runway extended through multiple data readouts and into Q1 of calendar 2025 MDNA11 is generally well tolerated and continues to demonstrate encouraging single-agent activity from Phase 1 portion of the ABILITY-1 Study including 100% and 70% reduction of target lesions in pancrea |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address |
|
| November 14, 2023 |
Exhibit 99.2 Management’s Discussion and Analysis For the Three and Six Months Ended September 30, 2023 DATE OF REPORT: November 13, 2023 MANAGEMENT’S DISCUSSION AND ANALYSIS The following management’s discussion and analysis (“MD&A”) has been prepared as at November 7, 2023 for the three and six months ended September 30, 2023 and should be read in conjunction with the unaudited interim condensed |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant’s name into English) 2 Bloor St. W. 7th Floor Toronto, Ontario M4W 3E2 Canada (Address of |
|
| November 8, 2023 |
FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.2 FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company Medicenna Therapeutics Corp. (the “Company”) 2 Bloor Street West, 7th Floor Toronto, Ontario M4W 3E2 2. Date of Material Change October 27, 2023 3. News Release On October 27, 2023, the Company issued a news release through the services of Globe Newswire with respect to the material change described below. 4. Summary |
|
| November 8, 2023 |
Exhibit 99.1 Medicenna Announces Nasdaq Delisting and Cutback of Management Team The Company’s listing on the Toronto Stock Exchange will not be impacted TORONTO and HOUSTON, October 27, 2023 - Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of engineered cytokines, announced today that the Company r |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address o |
|
| October 25, 2023 |
EXHIBIT 99.1 Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors New data from the Phase 1 dose-escalation and evaluation portion of the trial will be presented at the Society of Immunotherapy for Cancer (SITC) Annual Meeting on November 4, 2023 Company expects to report initial results from |
|
| October 24, 2023 |
EXHIBIT 99.1 Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC) TORONTO and HOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, announced poster presentations at the 38th Annual Meeting |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address o |
|
| October 10, 2023 |
EXHIBIT 99.1 Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer Dr. Gardner brings over 30 years of experience leading clinical development to support innovative oncology programs and translational research at global biopharmaceutical companies and major academic institutions TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenn |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address o |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address o |
|
| October 3, 2023 |
EXHIBIT 99.1 Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy MDNA223 is a bifunctional Superkine designed to activate cancer-killing immune cells via the IL-2 receptor while simultaneously preventing their exhaustion by blocking PD-1 signalling MDNA223 demonstrated superior efficacy and extended survival in multiple immunologi |
|
| September 28, 2023 |
Medicenna Announces Results of Annual and Special Meeting of Shareholders EXHIBIT 99.1 Medicenna Announces Results of Annual and Special Meeting of Shareholders TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ, TSX: MDNA), a clinical-stage immuno-oncology company focused on the development of novel Superkines, today announced the voting results from the Company’s annual and special meeting of shar |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address |
|
| September 28, 2023 |
EXHIBIT 99.1 Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, announced that the Company will present preclinical results |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address |
|
| September 6, 2023 |
Medicenna to Participate at The H.C. Wainwright 25th Annual Global Investment Conference EXHIBIT 99.1 Medicenna to Participate at The H.C. Wainwright 25th Annual Global Investment Conference TORONTO and HOUSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, announced that Dr. Fahar Merchant, President and CEO is scheduled to p |
|
| August 28, 2023 |
EXHIBIT 99.1 Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella’s appointment demonstrates Medicenna’s continuing commitment to establish its presence in Boston, the leading biotechnology ecosy |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| August 28, 2023 |
Exhibit 99.1 Notice and Management Information Circular For the Annual and Special Meeting of Shareholders to be held on September 28, 2023 August 9, 2023 Medicenna Therapeutics Corp. Notice of Annual and Special Meeting of Shareholders NOTICE IS HEREBY GIVEN that the annual and special meeting (the “Meeting”) of shareholders of Medicenna Therapeutics Corp. (the “Corporation”) will be held on Sept |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| August 28, 2023 |
Exhibit 99.2 |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| August 14, 2023 |
EXHIBIT 99.1 Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management Company to grow business development, financing and clinical leadership in Boston by accessing top-biotech talent. Brent Meadows, MBA, joins as Chief Business Officer (CBO), bringing over 25 years of large pharma and biotech experience and a track record of multiple high-va |
|
| August 9, 2023 |
EXHIBIT 99.1 Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study - Durable anti-cancer activity was observed during monotherapy dose escalation without dose-limiting toxicities - Late-stage pancreatic cancer patient achieved 80% tumor shrinkage with complete regression observed in two of three metastatic lesions in the liver in respons |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| August 8, 2023 |
EXHIBIT 99.1 Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee Development Advisory Committee strengthened with the expertise and leadership of Dr. Yavari TORONTO and HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today the appointment of D |
|
| August 4, 2023 |
Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023 EXHIBIT 99.1 Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023 TORONTO and HOUSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today that it will host a conference call and live webcast on August 9, 2023 at 8:30AM ET to provide |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| August 1, 2023 |
EXHIBIT 99.1 Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology Medicenna Therapeutics Corp. has been granted U.S. Patent No. 11,680,090 titled “Interleukin-2 Fusion Proteins and Uses Thereof.” The patent covers a method for enhancing immune cell survival and proliferation or inhibiting cell death and therefore improving f |
|
| July 28, 2023 |
Interim condensed consolidated financial statements of Exhibit 99.1 Interim condensed consolidated financial statements of Medicenna Therapeutics Corp. (Expressed in Canadian Dollars) For the three months ended June 30, 2023 Medicenna Therapeutics Corp. Interim Condensed Consolidated Statements of Financial Position (Expressed in thousands of Canadian Dollars, except for share and per share amounts) (Unaudited) as at June 30, 2023 March 31, 2023 $ $ A |
|
| July 28, 2023 |
Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights Exhibit 99.5 Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights Safety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1 portion of the ABILITY Study as there were no protocol defined dose-limiting toxicities MDNA11 clinical update scheduled for August 9; conference call to discuss data from cohorts five and six, recommended dose fo |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of p |
|
| July 28, 2023 |
Exhibit 99.2 Management’s Discussion and Analysis For the Three Months Ended June 30, 2023 DATE OF REPORT: July 27, 2023 MANAGEMENT’S DISCUSSION AND ANALYSIS The following management’s discussion and analysis (“MD&A”) has been prepared as at July 27, 2023 for the three months ended June 30, 2023 and should be read in conjunction with the unaudited interim condensed consolidated financial statement |
|
| July 28, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Fahar Merchant, Chairman, President and Chief Executive Officer of Medicenna Therapeutics Corp. (“Medicenna”) certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Medicenna (the “issuer”) for the interim period ended June 30, 2023. 2. No mi |
|
| July 28, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Elizabeth Williams, Chief Financial Officer of Medicenna Therapeutics Corp. (“Medicenna”) certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Medicenna (the “issuer”) for the interim period ended June 30, 2023. 2. No misrepresentations: Ba |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of p |
|
| July 25, 2023 |
Medicenna Presents at National Brain Tumor Society's Research Round Table EXHIBIT 99.1 Medicenna Presents at National Brain Tumor Society's Research Round Table Medicenna's President and CEO, Dr. Fahar Merchant, was invited to participate and present at the Brain Cancer Research Roundtable organized by the National Brain Tumor Society (“NBTS”) The focus of the event was to explore ways to expedite development of novel therapies for brain cancer by leveraging real-world |
|
| July 6, 2023 |
Medicenna Extends Period to Exercise Certain Warrants EXHIBIT 99.1 Medicenna Extends Period to Exercise Certain Warrants TORONTO and HOUSTON, July 05, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of a total of 1,549,052 outstanding c |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of p |
|
| June 27, 2023 |
Management’s Discussion and Analysis For the Year Ended March 31, 2023 DATE OF REPORT: June 26, 2023 Exhibit 15.1 Management’s Discussion and Analysis For the Year Ended March 31, 2023 DATE OF REPORT: June 26, 2023 MANAGEMENT’S DISCUSSION AND ANALYSIS The following management’s discussion and analysis (“MD&A”) has been prepared as at June 20, 2023 for the year ended March 31, 2023 and should be read in conjunction with the audited consolidated financial statements of Medicenna Therapeutics Corp. |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN |
|
| June 27, 2023 |
Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights EXHIBIT 99.1 Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights MDNA11 demonstrates durable single-agent activity in forth-line metastatic pancreatic cancer patient with a partial response continuing for over 40 weeks and stable disease for over 70 weeks as a third-line treatment in a patient with metastatic melanoma MDNA11 clinical update is anticipated during calenda |
|
| June 27, 2023 |
CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.1 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, as the Chief Executive Officer of Medicenna Therapeutics Corp., certifies that, to the best of his knowledge and belief, the annual report on Form 20-F for the fiscal year ended March 31, 2023, which accompanies this certification, fully complies with the requirements of Section 13(a) or 15(d), as |
|
| June 27, 2023 |
CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.2 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, as the Chief Financial Officer of Medicenna Therapeutics Corp., certifies that, to the best of her knowledge and belief, the annual report on Form 20-F for the fiscal year ended March 31, 2023, which accompanies this certification, fully complies with the requirements of Section 13(a) or 15(d), as |
|
| June 27, 2023 |
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Elizabeth Williams, certify that: 1. I have reviewed this annual report on Form 20-F of Medicenna Therapeutics Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstanc |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of p |
|
| June 27, 2023 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.3 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in the Registration Statements on Forms F-10 (File No. 333-238905), Form S-8 (No. 333-240225) and Form F-3 (No. 333-269868) of Medicenna Therapeutics Corp. of our report dated June 26, 2023, relating to the consolidated financial statements, which appears in this Annual Report |
|
| June 27, 2023 |
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Fahar Merchant, certify that: 1. I have reviewed this annual report on Form 20-F of Medicenna Therapeutics Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances u |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| April 27, 2023 |
Medicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement EXHIBIT 99.1 Medicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement TORONTO and HOUSTON, April 27, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that on April 25, 2023 it received a notice (the “Extension Notice”) from the Nasdaq Stock Market LLC (“Nas |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| April 18, 2023 |
Medicenna to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference EXHIBIT 99.1 Medicenna to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference TORONTO and HOUSTON, April 18, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will participate in a fireside chat and management |
|
| April 17, 2023 |
Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting EXHIBIT 99.1 Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting - IL-13 Superkines provide a versatile strategy for targeted delivery of anti-cancer agents to IL-13Rα2, which is overexpressed in many solid tumors but minimally expressed in normal tissues - MDNA132 and MDNA213 are novel IL-13 Superkines that are highly specific and preferentially accumulate in the microe |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| March 30, 2023 |
EXHIBIT 99.1 Medicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1/2 ABILITY Study - Additional evidence of durable anti-cancer activity with MDNA11 monotherapy seen in latest radiographic scans from first four dose escalation cohorts - Continued tumor reduction and complete regression of one of three metastatic lesions in fourth-line pancreatic cancer patient with |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| March 15, 2023 |
Medicenna Announces Upcoming Presentation at the AACR Annual Meeting EXHIBIT 99.1 Medicenna Announces Upcoming Presentation at the AACR Annual Meeting TORONTO and HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the publication of an abstract that has been accepted for a poster presentation at the American Association for Cancer Re |
|
| March 15, 2023 |
6-K 1 f6k031023.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario |
|
| March 2, 2023 |
6-K 1 f6k030223.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario |
|
| March 2, 2023 |
Medicenna to Present at the Oppenheimer 33rd Annual Healthcare Conference EXHIBIT 99.1 Medicenna to Present at the Oppenheimer 33rd Annual Healthcare Conference TORONTO and HOUSTON, March 02, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a fireside chat |
|
| February 23, 2023 |
MEDICENNA THERAPEUTICS CORP. 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2 MEDICENNA THERAPEUTICS CORP. 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2 Canada February 23, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Daniel Crawford RE: Medicenna Therapeutics Corp. Registration Statement on Form F-3 Filed February 17, 2023 File No. 333- 269868 Acceleration Request D |
|
| February 17, 2023 |
Medicenna Establishes At-the-Market Sales Facility EXHIBIT 99.1 Medicenna Establishes At-the-Market Sales Facility TORONTO and HOUSTON, Feb. 17, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, announced today that it has entered into a sales agreement with Oppenheimer & Co. Inc. (“Oppenheimer & Co.”) acting as sales agent (the “Sales Agreement” |
|
| February 17, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Medicenna Therapeutics, Corp. |
|
| February 17, 2023 |
As filed with the Securities and Exchange Commission on February 17, 2023 F-3 1 f3021623.htm FORM F-3 As filed with the Securities and Exchange Commission on February 17, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Medicenna Therapeutics Corp. (Exact name of Registrant as specified in its charter) Canada (Federal) (Province or other jurisdiction of inc |
|
| February 17, 2023 |
Exhibit 1.2 MEDICENNA THERAPEUTICS CORP. Common Shares SALES AGREEMENT February 17, 2023 Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Medicenna Therapeutics Corp., a corporation existing under the laws of Canada (the “Company”), confirms its agreement (this “Agreement”) with Oppenheimer & Co. Inc. (the “Agent”), as follows: 1. Issuance and Sale of Shares. T |
|
| February 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address |
|
| February 15, 2023 |
MDNA / Medicenna Therapeutics Corp. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 Medicenna Therapeutics Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 58490H107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2023 |
MDNA / Medicenna Therapeutics Corp. / Merchant Fahar - SC 13G/A Passive Investment SC 13G/A 1 sc13ga021423.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Medicenna Therapeutics Corp. (Name of Issuer) Common Shares, No Par Value (Title of Class of Securities) 58490H107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| February 14, 2023 |
EX-99.1 2 exh991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common shares of Medicenna Therapeutics Corp. and further agree that this agreement be inclu |
|
| February 7, 2023 |
EX-99.2 3 exh992.htm EXHIBIT 99.2 Exhibit 99.2 Management’s Discussion and Analysis For the Three and Nine Months Ended December 31, 2022 DATE OF REPORT: February 6, 2023 MANAGEMENT’S DISCUSSION AND ANALYSIS The following management’s discussion and analysis (“MD&A”) has been prepared as at February 6, 2023 for the three and nine months ended December 31, 2022 and should be read in conjunction wit |
|
| February 7, 2023 |
Medicenna Reports Third Quarter Fiscal 2023 Financial Results and Operational Highlights Exhibit 99.5 Medicenna Reports Third Quarter Fiscal 2023 Financial Results and Operational Highlights Phase 1/2 ABILITY study advancing to sixth dose escalation cohort following positive review of safety and pharmacodynamic data from fifth cohort Initial PK/PD data from ABILITY’s fifth dose escalation cohort expected alongside updated anti-tumor data in calendar Q1 2023 $36.2 million in cash and c |
|
| February 7, 2023 |
Three months ended December 31, Exhibit 99.1 Interim condensed consolidated financial statements of Medicenna Therapeutics Corp. (Expressed in Canadian Dollars) For the three and nine months ended December 31, 2022 Medicenna Therapeutics Corp. Interim Condensed Consolidated Statements of Financial Position (Expressed in thousands of Canadian Dollars, except for share and per share amounts) (Unaudited) as at December 31, 2022 Mar |
|
| February 7, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Fahar Merchant, Chairman, President and Chief Executive Officer of Medicenna Therapeutics Corp. (“Medicenna”) certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Medicenna (the “issuer”) for the interim period ended December 31, 2022. 2. N |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address |
|
| February 7, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Elizabeth Williams, Chief Financial Officer of Medicenna Therapeutics Corp. (“Medicenna”) certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Medicenna (the “issuer”) for the interim period ended December 31, 2022. 2. No misrepresentations |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address o |
|
| January 31, 2023 |
Medicenna to Present at the 2023 Guggenheim Oncology Conference EXHIBIT 99.1 Medicenna to Present at the 2023 Guggenheim Oncology Conference TORONTO and HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a fireside chat at the 20 |
|
| January 26, 2023 |
EXHIBIT 99.1 Medicenna to Announce Third Quarter Fiscal 2023 Financial Results and Operational Highlights on Tuesday, February 7, 2023 TORONTO and HOUSTON, Jan. 26, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on February 7, |
|
| January 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address o |
|
| January 5, 2023 |
EXHIBIT 99.1 Medicenna Strengthens Intellectual Property Protection for MDNA11 and BiSKITs? Programs with Issuance of U.S. Patent - Patent covers methods of treating cancer with an IL-2 Superkine and PD1/PDL1 or CTLA-4 checkpoint inhibitor, administered in combination or as a single agent BiSKIT? TORONTO and HOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (?Medicenna? or ?th |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address o |
|
| November 10, 2022 |
EXHIBIT 99.1 Medicenna Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 ABILITY Study of MDNA11 at the SITC Annual Meeting - MDNA11’s selectivity and dose-dependent stimulation of anti-cancer immune cells indicates potential for increased anti-tumor activity with continued dose escalation - New data reaffirm MDNA11’s potential to overcome the major safety, pharmacokinetic, |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address |
|
| November 4, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Elizabeth Williams, Chief Financial Officer of Medicenna Therapeutics Corp. (?Medicenna?) certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Medicenna (the ?issuer?) for the interim period ended September 30, 2022. 2. No misrepresentation |
|
| November 4, 2022 |
Three months ended September 30, Exhibit 99.1 Interim condensed consolidated financial statements of Medicenna Therapeutics Corp. (Expressed in Canadian Dollars) For the three and six months ended September 30, 2022 Medicenna Therapeutics Corp. Interim Condensed Consolidated Statements of Financial Position (Expressed in thousands of Canadian Dollars, except for share and per share amounts) (Unaudited) as at September 30, 2022 Ma |
|
| November 4, 2022 |
Exhibit 99.5 Medicenna Reports Second Quarter Fiscal 2023 Financial Results and Operational Highlights - Results from low and mid-dose escalation cohorts in Phase 1/2 ABILITY study show tumor control in 5 of 14 evaluable patients, including a confirmed partial response in pancreatic cancer - $40 million in cash, cash equivalents, and marketable securities at September 30, 2022, provides runway int |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address |
|
| November 4, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Fahar Merchant, Chairman, President and Chief Executive Officer of Medicenna Therapeutics Corp. (?Medicenna?) certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Medicenna (the ?issuer?) for the interim period ended September 30, 2022. 2. |
|
| November 4, 2022 |
Exhibit 99.2 Management?s Discussion and Analysis For the Three and Six Months Ended September 30, 2022 DATE OF REPORT: November 3, 2022 MANAGEMENT?S DISCUSSION AND ANALYSIS The following management?s discussion and analysis (?MD&A?) has been prepared as at November 3, 2022 for the three and six months ended September 30, 2022 and should be read in conjunction with the unaudited interim condensed |
|
| October 28, 2022 |
Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement EXHIBIT 99.1 Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement TORONTO and HOUSTON, Oct. 28, 2022 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that on October 25, 2022, it received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address o |
|
| October 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address o |
|
| October 25, 2022 |
EXHIBIT 99.1 Medicenna to Announce Second Quarter Fiscal 2023 Financial Results and Operational Highlights on Friday, November 4, 2022 TORONTO and HOUSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on November 4, |
|
| October 20, 2022 |
MDNA / Medicenna Therapeutics Corp. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Medicenna Therapeutics Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 58490H107 (CUSIP Number) August 10, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| October 17, 2022 |
6-K 1 f6k101722.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontar |
|
| October 17, 2022 |
Exhibit 99.1 MEDICENNA THERAPEUTICS CORP. - and ? TSX TRUST COMPANY FIRST SUPPLEMENTAL WARRANT INDENTURE Dated as of October 17, 2022 THIS FIRST SUPPLEMENTAL WARRANT INDENTURE is dated the 17th day of October, 2022. BETWEEN: MEDICENNA THERAPEUTICS CORP., a corporation existing under the laws of Canada; (hereinafter called the ?Corporation?); AND: TSX TRUST COMPANY, a trust company existing under t |
|
| October 5, 2022 |
EXHIBIT 99.1 Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting TORONTO and HOUSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (?Medicenna? or ?the Company?) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the acceptance of two abstracts for poster presentations at the Society for Immunothe |
|
| October 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address o |
|
| September 30, 2022 |
Medicenna Extends Period to Exercise Certain Warrants EXHIBIT 99.1 Medicenna Extends Period to Exercise Certain Warrants TORONTO and HOUSTON, Sept. 30, 2022 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (?Medicenna? or the ?Company?) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of the common share purchase warrant |
|
| September 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address |
|
| September 28, 2022 |
EXHIBIT 99.1 Medicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11?s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 ABILITY Study Confirmed partial response in fourth-line metastatic pancreatic cancer patient, who had previously failed chemotherapy and checkpoint inhibitor therapy, supports MDNA11?s single-agent potential in advanced solid tu |
|
| September 28, 2022 |
6-K 1 f6k092822.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ont |
|
| September 22, 2022 |
EXHIBIT 99.1 Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022 - Single agent Anti-PD1-IL-2 BiSKIT? showed superior efficacy compared to a combination of an anti-PD1 antibody with an IL-2 Superkine in murine models of colon, skin, and breast cancer -IL-4/IL-13 Super-antagonist displayed mo |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address |
|
| September 22, 2022 |
Report of Voting Results Medicenna Therapeutics Corp. Exhibit 99.1 Report of Voting Results Medicenna Therapeutics Corp. In accordance with Section 11.3 of National Instrument 51-102, the following describes the matters voted upon and the outcome of the votes at the annual meeting of shareholders of Medicenna Therapeutics Corp. (the ?Corporation?) held virtually on September 21, 2022. 1. Based on the proxies received and the votes by ballot, each of |
|
| September 21, 2022 |
Medicenna Announces Results of Annual Meeting of Shareholders EXHIBIT 99.1 Medicenna Announces Results of Annual Meeting of Shareholders TORONTO and HOUSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (?Medicenna? or the ?Company?) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the voting results from the Company?s annual meeting of shareholders held today, September 21, 2022 (the "Meeting"). Medicenna |
|
| September 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address |
|
| September 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address |
|
| September 13, 2022 |
EXHIBIT 99.1 Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA? (pembrolizumab) in ABILITY Trial ABILITY Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with Merck?s KEYTRUDA? (pembrolizumab) for treatment of patients with advanced solid tumors TORONTO and HOUSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) - Medice |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address |
|
| September 8, 2022 |
Medicenna to Present at Investor and Scientific Conferences in September EXHIBIT 99.1 Medicenna to Present at Investor and Scientific Conferences in September TORONTO and HOUSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (?Medicenna? or ?the Company?) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that the Company management and scientific teams will present at the following investor and scientific conferences th |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| August 22, 2022 |
Exhibit 99.1 Notice and Management Information Circular For the Annual Meeting of Shareholders to be held on September 21, 2022 August 2, 2022 Medicenna Therapeutics Corp. Notice of Annual Meeting of Shareholders NOTICE IS HEREBY GIVEN that the annual meeting (the ?Meeting?) of shareholders of Medicenna Therapeutics Corp. (the ?Corporation?) will be held on September 21, 2022 at 10:00 a.m. (Toront |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| August 22, 2022 |
Exhibit 99.2 |
|
| August 22, 2022 |
FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company Medicenna Therapeutics Corp. (the ?Company?) 2 Bloor Street West, 7th Floor, Toronto, Ontario M4W 3E2 2. Date of Material Change August 9, 2022 3. News Release On August 9, 2022, the Company issued news releases through the services of Globe Newswire with respect to the material change described below. 4. Summary of M |
|
| August 15, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Elizabeth Williams, Chief Financial Officer of Medicenna Therapeutics Corp. (?Medicenna?) certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Medicenna (the ?issuer?) for the interim period ended June 30, 2022. 2. No misrepresentations: Ba |
|
| August 15, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Fahar Merchant, Chairman, President and Chief Executive Officer of Medicenna Therapeutics Corp. (?Medicenna?) certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Medicenna (the ?issuer?) for the interim period ended June 30, 2022. 2. No mi |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| August 15, 2022 |
Exhibit 99.2 Management?s Discussion and Analysis For the Three Months Ended June 30, 2022 DATE OF REPORT: August 12, 2022 MANAGEMENT?S DISCUSSION AND ANALYSIS The following management?s discussion and analysis (?MD&A?) has been prepared as at August 12, 2022 for the three months ended June 30, 2022 and should be read in conjunction with the unaudited interim condensed consolidated financial state |
|
| August 15, 2022 |
Common shares issued and outstanding Exhibit 99.1 Interim condensed consolidated financial statements of Medicenna Therapeutics Corp. (Expressed in Canadian Dollars) For the three and nine months ended June 30, 2022 Medicenna Therapeutics Corp. Interim Condensed Consolidated Statements of Financial Position (Expressed in thousands of Canadian Dollars, except for share and per share amounts) (Unaudited) as at June 30, 2022 March 31, 2 |
|
| August 15, 2022 |
Exhibit 99.5 Medicenna Reports First Quarter Fiscal 2023 Financial Results and Operational Highlights - Extended Cash Runway Into 2024 With US$20 Million Raise To Complete Phase 1/2 ABILITY Study And Advance Pipeline - New MDNA11 Data From Dose Escalation in ABILITY Study Shows Tumor Control In Four Of Ten Evaluable Patients Including Unconfirmed Partial Response In Pancreatic Cancer Patient - ABI |
|
| August 11, 2022 |
6-K 1 tm2222517d36k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, On |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| August 11, 2022 |
\ Exhibit 99.1 MEDICENNA THERAPEUTICS CORP. - and - TSX TRUST COMPANY WARRANT INDENTURE August 11, 2022 TABLE OF CONTENTS Article 1 INTERPRETATION 6 1.1 Definitions 6 1.2 Words Importing the Singular 11 1.3 Interpretation not Affected by Headings 11 1.4 Day not a Business Day 11 1.5 Time of the Essence 11 1.6 Governing Law 11 1.7 Meaning of ?outstanding? for Certain Purposes 11 1.8 Currency 11 1.9 |
|
| August 11, 2022 |
Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline Exhibit 99.1 Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline TORONTO and HOUSTON, August 11, 2022 - Medicenna Therapeutics Corp. (?Medicenna? or the ?Company?) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immunotherapy company, is pleased to announce the closing of its previously announced marketed underwritten public offering of units (the ?Units?) |
|
| August 10, 2022 |
PROSPECTUS SUPPLEMENT TO SHORT FORM BASE SHELF PROSPECTUS DATED JULY 28, 2020 TABLE OF CONTENTS ??Filed Pursuant to General Instruction II.L. of Form F-10? ??File No. 333-238905? No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus supplement (?Prospectus Supplement?), together with the accompanying short form base shelf prospectus (?Prospectus?) dated July 28, 2020 to which it relates, a |
|
| August 9, 2022 |
Exhibit 99.2 13,333,334 COMMON SHARES WARRANTS TO PURCHASE 13,333,334 COMMON SHARES Medicenna Therapeutics Corp. UNDERWRITING AGREEMENT August 9, 2022 Guggenheim Securities, LLC As Representative of the several Underwriters named in Schedule I attached hereto c/o Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 Ladies/Gentlemen: Medicenna Therapeutics Corp., a corporation exi |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| August 9, 2022 |
Subject to completion, dated August 8, 2022 TABLE OF CONTENTS ??Filed Pursuant to General Instruction II.L. of Form F-10? ??File No. 333-238905? Information contained herein is subject to completion or amendment. A registration statement relating to these securities has been filed with the United States Securities Exchange Commission. This preliminary prospectus supplement and the accompanying base shelf prospectus shall not constitute an o |
|
| August 9, 2022 |
Consent of McCarthy Tétrault LLP Exhibit 99.3 August 9, 2022 Consent of McCarthy T?trault LLP We hereby consent to the use of our name on the cover page and under the headings ?Documents Filed as Part of the U.S. Registration Statement? and ?Legal Matters?, and to the reference to our name and use of our opinion under the headings ?Eligibility for Investment? and ?Certain Canadian Federal Income Tax Considerations? in the prospec |
|
| August 9, 2022 |
Medicenna Announces Pricing of US$20 Million Public Offering of Units Exhibit 99.1 Medicenna Announces Pricing of US$20 Million Public Offering of Units TORONTO and HOUSTON, August 9, 2022 - Medicenna Therapeutics Corp. (?Medicenna? or the ?Company?) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immunotherapy company, announced today that it has priced its previously-announced marketed underwritten public offering of 13,333,334 units (the ?Unit?) of the Company in the |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| August 9, 2022 |
PROSPECTUS SUPPLEMENT TO SHORT FORM BASE SHELF PROSPECTUS DATED JULY 28, 2020 TABLE OF CONTENTS ??Filed Pursuant to General Instruction II.L. of Form F-10? ??File No. 333-238905? No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus supplement (?Prospectus Supplement?), together with the accompanying short form base shelf prospectus (?Prospectus?) dated July 28, 2020 to which it relates, a |
|
| August 9, 2022 |
Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units Exhibit 99.1 Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units TORONTO and HOUSTON, August 8, 2022 - Medicenna Therapeutics Corp. (?Medicenna? or the ?Company?) (Nasdaq: MDNA, TSX: MDNA), a clinical stage immunotherapy company, announced today the launch of a marketed underwritten public offering of units of the Company (the ?Units?) in the United States (the ?Offe |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of |
|
| August 5, 2022 |
EXHIBIT 99.1 Medicenna to Announce First Quarter Fiscal 2023 Financial Results and Operational Highlights on Monday, August 15, 2022 TORONTO and HOUSTON, Aug. 05, 2022 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. ("Medicenna" or ?the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on August 15, 20 |
|
| July 27, 2022 |
6-K 1 f6k072722.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario |
|
| July 27, 2022 |
EXHIBIT 99.1 Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11?s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study - Tumor control was achieved in four of ten evaluable patients with advanced solid tumors unresponsive to other treatments enrolled in the ABILITY Study?s low and mid-stage dose escalation cohorts - Study?s fifth dose-escalation cohort is op |
|
| June 22, 2022 |
Exhibit 4.3 CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS ?[***]?) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THE INFORMATION AS PRIVATE OR CONFIDENTIAL. Revised version of Exclusive Equity Agreement between The board of Trustees of the Leland Stanford Junior University and Medicenna Therapeutics, Inc. e |
|
| June 22, 2022 |
Exhibit 4.16 CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS ?[***]?) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THE INFORMATION AS PRIVATE OR CONFIDENTIAL. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) made with effect from the 12th day of December, 2016 (the ?Effective Date?), BETWEEN: |
|
| June 22, 2022 |
Exhibit 4.15 July 28, 2021 Rosemina Merchant. 2 Bloor St. W, 7th Floor Toronto, ON M4W 3E2 Dear Rosemina, We are asking you to agree to certain changes to the written employment agreement dated January 1, 2013 as amended March 1, 2015, October 1, 2016, September 21, 2017 and November 3, 2020 (your "Employment Agreement") a copy of which is enclosed with this amendment letter). We have set out the |
|
| June 22, 2022 |
Exhibit 4.10 November 3, 2020 Fahar Merchant 2 Bloor St. W, 7th Floor Toronto, ON M4W 3E2 Dear Fahar, We are asking you to agree to certain changes to the written employment agreement dated January 1, 2013 as amended March 1, 2015, October 1, 2016 and September 21, 2017 (your "Employment Agreement") a copy of which is enclosed with this amendment letter). We have set out the changes that will be m |
|
| June 22, 2022 |
Warrant indenture dated December 21, 2018 between the Company and TSX Trust Company Exhibit 2.1 MEDICENNA THERAPEUTICS CORP. as the Corporation and TSX TRUST COMPANY as the Warrant Agent WARRANT INDENTURE Providing for the Issue of Warrants Dated as of December 21, 2018 TABLE OF CONTENTS Page ARTICLE 1 INTERPRETATION 1 1.1 Definitions 1 1.2 Gender and Number 6 1.3 Headings, Etc 6 1.4 Day not a Business Day 6 1.5 Time of the Essence 7 1.6 Monetary References 7 1.7 Applicable Law 7 |
|
| June 22, 2022 |
Letter of Davidson & Company LLP Exhibit 15.5 June 21, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 16F of Form 20-F for the fiscal year ended March 31, 2022 of Medicenna Therapeutics Corp. (the ?Company?) and are in agreement with the statements contained in paragraphs 2, 3 and 4 of Item 16F therein. We have no basis to agree or disagree with the other st |
|
| June 22, 2022 |
Exhibit 15.2 AUDIT COMMITTEE CHARTER 1. Purpose The primary function of the audit committee (the ?Committee?) is to assist the Board of Directors (the ?Board?) of Medicenna Therapeutics Corp. (the ?Company?) in fulfilling its oversight of, and recommend appropriate actions with respect to (i) the integrity of the Company?s financial statements, accounting and financial reporting processes, system |
|
| June 22, 2022 |
Exhibit 13.1 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, as the Chief Executive Officer of Medicenna Therapeutics Corp., certifies that, to the best of his knowledge and belief, the annual report on Form 20-F for the fiscal year ended March 31, 2022, which accompanies this certification, fully complies with the requirements of Section 13(a) or 15(d), as |
|
| June 22, 2022 |
United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN |
|
| June 22, 2022 |
Management Discussion and Analysis of the Company for the year ended March 31, 2022. Exhibit 15.1 Management?s Discussion and Analysis For the Year Ended March 31, 2022 DATE OF REPORT: June 21, 2022 MANAGEMENT?S DISCUSSION AND ANALYSIS The following management?s discussion and analysis (?MD&A?) has been prepared as at June 21, 2022 for the year ended March 31, 2022 and should be read in conjunction with the audited consolidated financial statements of Medicenna Therapeutics Corp. |
|
| June 22, 2022 |
Exhibit 4.2 CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS ?[***]?) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THE INFORMATION AS PRIVATE OR CONFIDENTIAL. Revised version of Exclusive Equity Agreement between The board of Trustees of the Leland Stanford Junior University and Medicenna Therapeutics, Inc. e |
|
| June 22, 2022 |
Exhibit 4.6 CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS ?[***]?) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THE INFORMATION AS PRIVATE OR CONFIDENTIAL. NATIONAL INSTITUTES OF HEALTH START-UP PATENT LICENSE AGREEMENT ? EXCLUSIVE COVER PAGE For the NIH?s internal use only: License Number: L-236-2013/0 Li |
|
| June 22, 2022 |
Exhibit 4.7 CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS ?[***]?) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THE INFORMATION AS PRIVATE OR CONFIDENTIAL. STATE OF TEXAS COUNTY OF TRAVIS This CANCER RESEARCH GRANT CONTRACT (?Contract?) is by and between the Cancer Prevention and Research Institute of Texa |
|
| June 22, 2022 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EX-99.2 3 ex388202.htm EXHIBIT 99.2 Exhibit 99.2 Consolidated financial statements of Medicenna Therapeutics Corp. (Expressed in Canadian Dollars) For the years ended March 31, 2022, 2021 and 2020 Report of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors of Medicenna Therapeutics Corp. Opinion on the Financial Statements We have audited the accompanying con |
|
| June 22, 2022 |
Exhibit 4.18 November 3, 2020 Elizabeth Williams 2 Bloor St. W, 7th Floor Toronto, ON M4W 3E2 Dear Elizabeth, We are asking you to agree to certain changes to the written employment agreement dated December 12, 2016 as amended September 21, 2017 (your "Employment Agreement") a copy of which is enclosed with this amendment letter). We have set out the changes that will be made to the terms of your |
|
| June 22, 2022 |
Exhibit 4.11 July 28, 2021 Fahar Merchant 2 Bloor St. W, 7th Floor Toronto, ON M4W 3E2 Dear Fahar, We are asking you to agree to certain changes to the written employment agreement dated January 1, 2013 as amended March 1, 2015, October 1, 2016, September 21, 2017 and November 3, 2020 (your "Employment Agreement") a copy of which is enclosed with this amendment letter). We have set out the change |
|
| June 22, 2022 |
Consent of independent registered public accounting firm (Davidson & Company LLP) (PCAOB ID #731) Exhibit 15.4 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the use of our report dated June 21, 2022, relating to the consolidated financial statements of Medicenna Therapeutics Corp for the year ended March 31, 2020, appearing in this Annual Report on Form 20-F for the year ended March 31, 2022. We also consent to the incorporation by reference in the Registration |
|
| June 22, 2022 |
Exhibit 13.2 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, as the Chief Financial Officer of Medicenna Therapeutics Corp., certifies that, to the best of her knowledge and belief, the annual report on Form 20-F for the fiscal year ended March 31, 2022, which accompanies this certification, fully complies with the requirements of Section 13(a) or 15(d), as |
|
| June 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of p |
|
| June 22, 2022 |
Exhibit 4.14 November 3, 2020 Rosemina Merchant. 2 Bloor St. W, 7th Floor Toronto, ON M4W 3E2 Dear Rosemina, We are asking you to agree to certain changes to the written employment agreement dated January 1, 2013 as amended March 1, 2015, October 1, 2016 and September 21, 2017 (your "Employment Agreement") a copy of which is enclosed with this amendment letter). We have set out the changes that wi |
|
| June 22, 2022 |
2017 Stock Option Plan (including form of option agreement) Exhibit 4.1 MEDICENNA THERAPEUTICS CORP. 2017 STOCK OPTION PLAN 1. PURPOSE OF THE PLAN 1.1 The purpose of the Plan is to attract, retain and motivate persons of training, experience and leadership as key service providers to the Corporation and its Subsidiaries, including their directors, officers and employees, and to advance the interests of the Corporation by providing such persons with the opp |
|
| June 22, 2022 |
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer Exhibit 12.2 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Elizabeth Williams, certify that: 1. I have reviewed this annual report on Form 20-F of Medicenna Therapeutics Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstanc |
|
| June 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of p |
|
| June 22, 2022 |
Code of Business Conduct and Ethics Exhibit 11.1 CODE OF BUSINESS CONDUCT AND ETHICS 1. Statement of Policy Medicenna Therapeutics Corp. (the ?Company?) is committed to the highest standards of legal and ethical business conduct. This Code of Business Conduct and Ethics (the ?Code?) summarizes the legal, ethical and regulatory standards that the Company must follow and is a reminder to the directors, officers and employees of the se |
|
| June 22, 2022 |
Exhibit 15.3 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in the Registration Statements on Forms F-10 (File No. 333-238905) and Form S-8 (No. 333-240225) of Medicenna Therapeutics Corp. of our report dated June 21, 2022, relating to the consolidated financial statements, which appears in this Annual Report on Form 20-F. /s/Pricewater |
|
| June 22, 2022 |
Exhibit 4.13 September 21, 2017 Rosemina (Nina) Merchant 1920 Yonge Street, 2nd Floor Toronto, ON Dear Nina: We are asking you to agree to certain changes to your written employment agreement dated January 1, 2013 as amended March 1, 2015 and October 1, 2016 (your "Employment Agreement") a copy of which is enclosed with this amendment letter). We have set out the changes that will be made to the t |
|
| June 22, 2022 |
Exhibit 4.5 AMENDMENT TO EXCLUSIVE (EQUITY) AGREEMENTS This is an amendment (this ?Amendment?) to the Exclusive (Equity) Agreement for Stanford dockets S11-072 and S11-184 (the ?Agreement?) entered into as of August 21, 2015 between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (?Stanford?), an institution of higher education having powers under the laws of the State of California |
|
| June 22, 2022 |
Exhibit 4.8 CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS ?[***]?) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THE INFORMATION AS PRIVATE OR CONFIDENTIAL. THIS EMPLOYMENT AGREEMENT (the ?Agreement?) dated for reference the 1st day of January, 2013 (the ?Effective Date?), and amended the 1st day of March 2 |
|
| June 22, 2022 |
Exhibit 4.9 September 21, 2017 Fahar Merchant 1920 Yonge Street, 2nd Floor Toronto, ON Dear Fahar: We are asking you to agree to certain changes to your written employment agreement dated January 1, 2013 and as amended March 1, 2015 and October 1, 2016 (your ?Employment Agreement?) a copy of which is enclosed with this amendment letter). We have set out the changes that will be made to the terms o |
|
| June 22, 2022 |
Exhibit 4.12 CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS ?[***]?) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THE INFORMATION AS PRIVATE OR CONFIDENTIAL. THIS EMPLOYMENT AGREEMENT (the ?Agreement?) dated for reference the 1St day of January, 2013 (the ?Effective Date?), and amended the 1st day of March |
|
| June 22, 2022 |
Exhibit 1.1 Certificate of Continuance Certificat de prorogation Canada Business Corporations Act Loi canadienne sur les soci?t?s par actions Medicenna Therapeutics Corp. Corporation number / Num?ro de soci?t? 1049266-3 Corporation number / Num?ro de soci?t? I HEREBY CERTIFY that the above-named corporation, the articles of continuance of which are attached, is continued under section 187 of the C |
|
| June 22, 2022 |
Exhibit 4.17 September 21, 2017 Elizabeth Williams 1920 Yonge Street, 2nd Floor Toronto, ON Dear Elizabeth: We are asking you to agree to certain changes to your written employment agreement dated December 12, 2016 (your ?Employment Agreement?) a copy of which is enclosed with this amendment letter). We have set out the changes that will be made to the terms of your Employment Agreement below. Ple |
|
| June 22, 2022 |
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer Exhibit 12.1 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Fahar Merchant, certify that: 1. I have reviewed this annual report on Form 20-F of Medicenna Therapeutics Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances u |
|
| June 22, 2022 |
Exhibit 4.19 July 28, 2021 Elizabeth Williams 2 Bloor St. W, 7th Floor Toronto, ON M4W 3E2 Dear Elizabeth, We are asking you to agree to certain changes to the written employment agreement dated December 12, 2016 as amended September 21, 2017 and November 3, 2021 (your "Employment Agreement") a copy of which is enclosed with this amendment letter). We have set out the change that will be made to t |
|
| June 22, 2022 |
EX-99.1 2 ex388200.htm EXHIBIT 99.1 Exhibit 99.1 ANNUAL INFORMATION FORM FOR THE YEAR ENDED MARCH 31, 2022 Unless otherwise indicated, all information in the Annual Information Form is presented as at and for the year ended March 31, 2022 June 21, 2022 TABLE OF CONTENTS INTRODUCTION AND FORWARD-LOOKING STATEMENTS 1 CORPORATE STRUCTURE 4 GENERAL DEVELOPMENT OF THE BUSINESS 6 NARRATIVE DESCRIPTION O |
|
| June 22, 2022 |
EXHIBIT 99.1 Medicenna Reports Fiscal Year 2022 Financial Results and Operational Highlights -Cash runway extended late into calendar Q2 2023 -Tumor control achieved following MDNA11 treatment in 3 out of 8 patients enrolled in first 3 dose escalation cohorts of the ABILITY Phase 1/2 Study. - Pharmacodynamic data show superior dose-dependent increase in stimulation of anti-cancer immune cells when |
|
| June 22, 2022 |
Management’s Discussion and Analysis For the Year Ended March 31, 2022 DATE OF REPORT: June 21, 2022 EX-99.3 4 ex388203.htm EXHIBIT 99.3 Exhibit 99.3 Management’s Discussion and Analysis For the Year Ended March 31, 2022 DATE OF REPORT: June 21, 2022 MANAGEMENT’S DISCUSSION AND ANALYSIS The following management’s discussion and analysis (“MD&A”) has been prepared as at June 21, 2022 for the year ended March 31, 2022 and should be read in conjunction with the audited consolidated financial stateme |
|
| June 22, 2022 |
Exhibit 4.4 AMENDMENT TO EXCLUSIVE (EQUITY) AGREEMENTS This is an amendment (this ?Amendment?) to the Exclusive (Equity) Agreement for Stanford dockets S10-200 and S14-174 (the ?Agreement?) entered into as of August 21, 2015 between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (?Stanford?), an institution of higher education having powers under the laws of the State of California |
|
| June 22, 2022 |
Warrant indenture dated October 17, 2019 between the Company and TSX Trust Company Exhibit 2.2 MEDICENNA THERAPEUTICS CORP. as the Corporation and TSX TRUST COMPANY as the Warrant Agent WARRANT INDENTURE Providing for the Issue of Warrants Dated as of October 17, 2019 TABLE OF CONTENTS Page ARTICLE 1 INTERPRETATION 1 1.1 Definitions. 1 1.2 Gender and Number. 6 1.3 Headings, Etc. 6 1.4 Day not a Business Day 6 1.5 Time of the Essence 7 1.6 Monetary References. 7 1.7 Applicable La |
|
| June 22, 2022 |
Exhibit 1.3 CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS ?[***]?) HAS BEEN EXCLUDED FROM THIS EXHIBITBECAUSE IT IS BOTH (I)NOT MATERIAL AND (II)THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THE INFORMATION AS PRIVATE OR CONFIDENTIAL. AMALGAMATION AGREEMENT THIS AMALGAMATION AGREEMENT is made and effective as of February 5, 2017. AMONG: A2 ACQUISITION CORP., a body corporate, incorporat |
|
| June 9, 2022 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Medicenna Strengthens Intellectual Property Protection for Superkine Platform with Issuance of U.S. Patent Patent covers composition and methods of treating degenerative diseases via administration of IL-4 and IL-13 Empowered Superkines Delivery of selected Bcl-2 family of proteins can prevent cell death, repair cell damage and restore cellular funct |
|
| June 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of p |
|
| June 7, 2022 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Medicenna to Announce Fiscal Year 2022 Financial Results and Operational Highlights on Wednesday, June 22, 2022 TORONTO and HOUSTON, June 07, 2022 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and li |
|
| June 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of p |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of pr |
|
| May 11, 2022 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11’s Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy Meeting - New data show that MDNA11 boosted the lymphocyte population by 2-fold without inducing significant increases in eosinophils (associated with toxicity) - MDNA11 selectively increased a sub-population |
|
| May 2, 2022 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Medicenna Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 ABILITY Study - Levels of Ki67+ expression by CD8+ T cells and NK cells increased by 17-fold and 10-fold, respectively, in the third cohort (30 µg/kg dose) when compared to baseline - NK cell / Treg and CD8+T cell / Treg r |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39458 Medicenna Therapeutics Corp. (Translation of registrant's name into English) 2 Bloor St. W., 7th Floor Toronto, Ontario M4W 3E2, Canada (Address of pr |
|
| April 27, 2022 |
Medicenna Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference EXHIBIT 99.1 Medicenna Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference TORONTO and HOUSTON, April 27, 2022 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (?Medicenna? or ?the Company?) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President and CEO and Elizabeth Williams, CFO of Medicenna, will at |
